21 December 2020 RASP-201 LSD1 LYSINE-SPECIFIC DEMETHYLASE 1 RASP-301 NPM1 NUCLEOPHOSMIN Rasna Therapeutics was formed in 2013 by a highly experienced industry team together with field-leading scientists, to focus on developing therapeutics to address the high unmet need that exists for AML and ot...
Rasna Therapeutics Inc. Tiziano Lazzaretti E-mail:tlazzaretti@rasna.com Clinical researchPhase II MORE ON THIS TOPIC Vaccines FDA Pauses Study of BioNTech’s Malaria Shot as Problems for Vaccine Space Mount March 5, 2025 · 2 min read